Publications

Has management of locally advanced intrahepatic cholangiocarcinoma evolved with the evidence? Trends and practice patterns from the National Cancer Database

LE Schlehner, RJ Ellis, HL Kalvin, TP Kingham, KC Soares, MI D'Angelica, ...

Has management of locally advanced intrahepatic cholangiocarcinoma evolved with the evidence? Trends and practice patterns from the National Cancer Database.

LE Schleimer, HL Kalvin, TP Kingham, K Soares, MI D'Angelica, ...

Immune checkpoint blockade induced sarcoid-like reaction mimicking progression of disease in a patient with microsatellite instable colorectal cancer: case report and review of …

F Keane, E Yogiaveetil, B Kezlarian, M Lagratta, NH Segal, G Abou-Alfa, ...

Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study

Dekker EN, van Dam JL, Janssen QP, Besselink MG, DeSilva A, Doppenberg D, van Eijck CHJ, Nasar N, et al.

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)

Nowak JA, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, Väyrynen J, Zhao M, et al.

Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B–Southwest Oncology Group 80702 (Alliance)

JC Brown, C Ma, Q Shi, F Couture, P Kuebler, P Kumar, B Tan, ...

Inter-reader agreement of imaging response after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma

JS Heiselman, N Horvat, B Agridag-Upcinar, O Yildirim, BL Ecker, ...

Inter-reader variability of imaging biomarkers for therapeutic response in pancreatic ductal adenocarcinoma.

JS Heiselman, N Horvat, B Agridag-Upcinar, O Yildirim, BL Ecker, ...

Intrahepatic cholangiocarcinoma: Recurrence patterns, genomics and survival.

P Chandra, Y Song, EN Drill, ACC Wei, NE Kemeny, A Cercek, ...

Intrahepatic Cholangiocarcinoma: Recuurence Patterns, Genomics and Survival

P Chandra, Y Song, E Drill, AC Wei, N Kemeny, A Cercek, L Connell, ...

Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial/leucovorin (NALIRIFOX) or nab-paclitaxel plus …

SR Chandana, ZA Wainberg, D Melisi, T Macarulla, RA Pazo Cid, ...

KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers

Gelfer R, Gulla A, Kalvin HL, Song Y, Harding J, Abou-Alfa GK, O'Reilly EM, Park W, et al.

LBA26 SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab …

K Ng, FS Ou, T Zemla, N McCleary, A Kalyan, M Shusterman, ...

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, et al.

Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer

O'Connor CA, Harrold E, Lin D, Walch H, Gazzo A, Ranganathan M, Kane S, Keane F, et al.

Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication

Singh I, Chou JF, Capanu M, Park J, Yu KH, Varghese AM, Park W, Zervoudakis A, et al.

Multi-institutional comparison of ablative 5-fraction mr-guided online adapted vs. 15/25-fraction ct-guided offline adapted radiation therapy for locally advanced pancreas cancer

MD Chuong, E O’Reilly, R Herrera, M Zinovoy, KE Mittauer, M Rubens, ...

Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer

Bojmar L, Zambirinis CP, Hernandez JM, Chakraborty J, Shaashua L, Kim J, Johnson KE, Hanna S, et al.

NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3

Wainberg ZA, M O'Reilly E

NALIRIFOX Versus FOLFOX as First-oLine Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): Real-World Comparative Overall (OS) Survival Analysis

E O'Reilly, J Li, M DerSarkissian, R Chang, M Cheng, L Yu, D Rane, ...

NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem plus NabP) in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Subgroup analysis of …

T Macarulla Mercade, RA Pazo Cid, M Womack, A Cubillo Gracian, ...

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29 …

MA Hussein, G Khan, SR Chandana, RA Pazo Cid, I Kiss, J Gallego, ...

Next-generation therapies for pancreatic cancer

CW Buckley, EM O’Reilly

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)

M Callahan, A Amin, FJ Kaye, MA Morse, MH Taylor, KJ Peltola, ...

Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.

W Park, J Zhang, F Dayyani, J Shan, R Liu, R Guo, EM O'Reilly, Z Liu, ...

Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) plus etrumadenant (etruma) plus chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC

KP Kim, MP Sarvise, T Macarulla, A Alistar, E O'Reilly, M Boakye, ...

Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo)+ etrumadenant (etruma)+ chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC

K Kim, M Ponz-Sarvise, T Macarulla, A Alistar, EM O’Reilly, M Boakye, ...

Plant-based diet and survival among patients with metastatic colorectal cancer: Findings from CALGB/SWOG 80405 (Alliance)

E Cheng, FS Ou, C Ma, AP Venook, HJ Lenz, EM O’Reilly, PT Campbell, ...

Postoperative adverse events following neoadjuvant therapy and surgery for borderline resectable pancreatic cancer in a phase 2 clinical trial (alliance A021501)

RA Snyder, TJ Zemla, Q Shi, D Segovia, SA Ahmad, EM O’Reilly, ...

Postoperative complications following neoadjuvant therapy and surgery in a phase 2 borderline resectable pancreatic cancer clinical trial (Alliance A021501).

RA Snyder, TJ Zemla, Q Shi, DI Segovia, S Ahmad, EM O'Reilly, ...

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease

Keane F, Chou JF, Walch H, Schoenfeld J, Singhal A, Cowzer D, Harrold E, O'Connor CA, et al.

Quality of life (QOL) for patients with esophageal cancer receiving trimodality therapy with induction chemotherapy, chemoradiation, and surgery: Results from CALGB 80803 …

KA Goodman, AC Dueck, B Fruth, AM Noonan, A Shergill, TS Bekaii-Saab, ...

Radiation Quality Control in the PROSPECT Trial

HJ Mamon, Q Shi, KS Smith, B Colgrove, J Quigley, G Nelson, M Weiser, ...

Radiation therapy quality assurance analysis of alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable …

LT Tchelebi, D Segovia, K Smith, Q Shi, TJ Fitzgerald, MD Chuong, ...

Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery

Dee EC, Ng VC, O'Reilly EM, Wei AC, Lobaugh SM, Varghese AM, Zinovoy M, Romesser PB, et al.

Salvage hepatic artery infusion chemotherapy after first-line systemic failure in patients with unresectable cholangiocarcinoma.

N Nasar, M Armstrong, JF Chou, M Gonen, K Soares, VP Balachandran, ...

Second-line chemotherapy in localized pancreatic cancer: a systematic review and meta-analysis

EN Dekker, RR Narayan, MG Besselink, CH van Eijck, MY Homs, ...

Somatic mismatch repair deficiency in pancreas cancer (PC): Immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses.

CA O'Connor, E Harrold, YT Lin, HS Walch, A Gazzo, SR Kane, F Keane, ...

Starting at the Front Line in Metastatic Pancreatic Cancers: As New Options Emerge, How Do You Select and Sequence?

ZA Wainberg, T Bekaii-Saab, E O'Reilly, S Pant

Survival after surgery for LAPC depends on post-induction CA19-9, CA19-9 decrease, performance status

E Dekker, D van Klaveren, Q Janssen, M Besselink, M Katz, E O’Reilly, ...

SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis

Yavas A, Ozcan K, Adsay NV, Balci S, Tarcan ZC, Hechtman JF, Luchini C, Scarpa A, et al.

T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with minimal residual disease in AMPLIFY-201, a phase 1 trial of a first-in-class amphiphile …

ZA Wainberg, S Pant, CD Weekes, M Furqan, PM Kasi, CE Devoe, ...

Targeting KRAS in cancer

Singhal A, Li BT, O'Reilly EM

Therapeutic developments in pancreatic cancer

Hu ZI, O'Reilly EM

115 Comprehensive spatial, transcriptomic, and genomic analysis of immunogenic biliary tract cancer

W Park, F Keane, HS Ozkan, A Richards, V Rudneva, D Khalil, K Soares, ...

1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)

A Schram, T Macarulla, J Cleary, C Neuzillet, D Arnold, KA Reiss, ...

1619P Health-related quality of life with nalirifox versus nab-paclitaxel+ gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC …

D Melisi, T Macarulla, C de la Fouchardiere, RAP Cid, S Chandana, ...

1626P A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer

AM Varghese, T Golan, M Schattner, C Ang, M Gutierrez, M Passhak, ...

597P Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)

M Weiser, Q Shi, GJ Chang, L Hakki, J Goldberg, R Auer, M Gollub, ...

765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C …

EM O’Reilly, MH O’Hara, G Fisher, RA Wolff, ZA Wainberg, AH Ko, ...